EDX Medical Group reposted this
Cambridge life science company EDX Medical Group plc, part of the Sir Chris Evans stable, has signed a distribution agreement with Caris Life Sciences® , a leading US-based nextgen AI TechBio and precision medicine company. EDX Medical and Caris will collaborate on a mutually exclusive basis in the UK and Nordic countries for a minimum of three years to distribute Caris’ portfolio of advanced and comprehensive molecular profiling services for clinical and research use. Caris’ solid tumour and liquid (blood) biopsy molecular profiling services, as well as AI solutions, will be available exclusively via EDX Medical immediately in the UK, Sweden, Denmark, Norway and Finland, with additional regions and products to follow. EDX Medical CEO Dr Mike Hudson said: “We are proud to have been selected by Caris to play a key role in jointly bringing these incredibly useful cancer tumour profiling services to the UK and key areas of Europe.” Dr David Spetzler, Caris Life Sciences President, added: “This collaboration aligns with Caris’ goal of enabling clinicians worldwide to make the best individualised treatment choices for their patients and ultimately helping to improve patient outcomes.” Based at Cambridge Science Park, EDX develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases. Sir Christopher Evans, Professor, said: “The signing of this agreement signifies a further major step forward in our strategy to provide clients with access to world-class diagnostic tools and services that can change the detection, treatment and outcome of illness for patients. “The pace of scientific advancement is such that for a patient with cancer who may only be able to provide one sample and urgently needs to start optimal treatment, reviewing their whole exome and transcriptome rather than a smaller selection of genes limited by current knowledge is clearly the most robust clinical approach. We could not wish for a better partner in this field than Caris.” Full article – https://lnkd.in/e2kWnbMq
